60; H460; H-460; NCIH460; NCI-HUT-460; NCI-460
DR   BTO; BTO_0002207
DR   CLO; CLO_0003601
DR   CLO; CLO_0008089
DR   EFO; EFO_0003044
DR   MCCL; MCC:0000356
DR   CLDB; cl1548
DR   4DN; 4DNSRZBU6PZA
DR   AddexBio; C0016003/39
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-2770
DR   ATCC; HTB-177
DR   BCRC; 60373
DR   BCRJ; 0416
DR   BioGRID_ORCS_Cell_line; 523
DR   BioSample; SAMN03471184
DR   BioSample; SAMN10987808
DR   cancercelllines; CVCL_0459
DR   CCLV; CCLV-RIE 0962
DR   CCRID; 1101HUM-PUMC000355
DR   CCRID; 1102HUM-NIFDC00086
DR   CCRID; 3101HUMSCSP584
DR   CCRID; 3101HUMTCHu205
DR   CCRID; 4201HUM-CCTCC00109
DR   CCTCC; GDC0109
DR   Cell_Model_Passport; SIDM00144
DR   CGH-DB; 199-1
DR   CGH-DB; 9186-4
DR   ChEMBL-Cells; CHEMBL3307677
DR   ChEMBL-Targets; CHEMBL396
DR   CLS; 305020
DR   Cosmic; 722064
DR   Cosmic; 724876
DR   Cosmic; 755469
DR   Cosmic; 844595
DR   Cosmic; 875852
DR   Cosmic; 877263
DR   Cosmic; 877407
DR   Cosmic; 897508
DR   Cosmic; 905943
DR   Cosmic; 911996
DR   Cosmic; 931371
DR   Cosmic; 947356
DR   Cosmic; 980964
DR   Cosmic; 1006534
DR   Cosmic; 1017826
DR   Cosmic; 1028956
DR   Cosmic; 1032436
DR   Cosmic; 1044245
DR   Cosmic; 1047102
DR   Cosmic; 1089231
DR   Cosmic; 1092621
DR   Cosmic; 1146917
DR   Cosmic; 1154605
DR   Cosmic; 1152502
DR   Cosmic; 1188592
DR   Cosmic; 1219077
DR   Cosmic; 1239922
DR   Cosmic; 1305349
DR   Cosmic; 1312334
DR   Cosmic; 1434967
DR   Cosmic; 1436013
DR   Cosmic; 1477420
DR   Cosmic; 1802310
DR   Cosmic; 1870275
DR   Cosmic; 1945869
DR   Cosmic; 1995579
DR   Cosmic; 1998463
DR   Cosmic; 2042872
DR   Cosmic; 2058650
DR   Cosmic; 2125199
DR   Cosmic; 2433756
DR   Cosmic; 2560230
DR   Cosmic; 2630413
DR   Cosmic; 2664114
DR   Cosmic; 2772154
DR   Cosmic-CLP; 905943
DR   DepMap; ACH-000463
DR   DSMZ; ACC-737
DR   DSMZCellDive; ACC-737
DR   EGA; EGAS00001000610
DR   EGA; EGAS00001002554
DR   ENCODE; ENCBS279XIV
DR   ENCODE; ENCBS398KLJ
DR   ENCODE; ENCBS428IIT
DR   ENCODE; ENCBS446PPO
DR   ENCODE; ENCBS460OUE
DR   ENCODE; ENCBS514AAA
DR   ENCODE; ENCBS515AAA
DR   ENCODE; ENCBS641PGO
DR   ENCODE; ENCBS657CEJ
DR   ENCODE; ENCBS686KKP
DR   ENCODE; ENCBS798ZFS
DR   ENCODE; ENCBS814QPR
DR   GDSC; 905943
DR   GEO; GSM2152
DR   GEO; GSM50216
DR   GEO; GSM50279
DR   GEO; GSM108853
DR   GEO; GSM108854
DR   GEO; GSM206493
DR   GEO; GSM253335
DR   GEO; GSM274737
DR   GEO; GSM274738
DR   GEO; GSM385522
DR   GEO; GSM385533
DR   GEO; GSM434334
DR   GEO; GSM513936
DR   GEO; GSM514322
DR   GEO; GSM743455
DR   GEO; GSM750809
DR   GEO; GSM784193
DR   GEO; GSM794288
DR   GEO; GSM799343
DR   GEO; GSM799406
DR   GEO; GSM827469
DR   GEO; GSM844652
DR   GEO; GSM844651
DR   GEO; GSM847076
DR   GEO; GSM887430
DR   GEO; GSM888510
DR   GEO; GSM1153414
DR   GEO; GSM1178473
DR   GEO; GSM1178474
DR   GEO; GSM1178475
DR   GEO; GSM1181352
DR   GEO; GSM1181361
DR   GEO; GSM1374746
DR   GEO; GSM1374747
DR   GEO; GSM1374748
DR   GEO; GSM1557134
DR   GEO; GSM2124676
DR   IARC_TP53; 21083
DR   IGRhCellID; NCI-H460%20GEO
DR   IZSLER; BS TCL 197
DR   KCB; KCB 2010102YJ
DR   KCLB; 30177
DR   LiGeA; CCLE_338
DR   LINCS_LDP; LCL-1784
DR   Lonza; 728
DR   NCI-DTP; NCI-H460
DR   PharmacoDB; NCIH460_1114_2019
DR   PRIDE; PXD005940
DR   PRIDE; PXD005942
DR   PRIDE; PXD005946
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_0459
DR   PubChem_Cell_line; CVCL_0459
DR   SKY/M-FISH/CGH; 2798
DR   Wikidata; Q54908057
RX   PubMed=1311061;
RX   PubMed=1563005;
RX   PubMed=2041050;
RX   PubMed=2388294;
RX   PubMed=3335022;
RX   PubMed=3940644;
RX   PubMed=7718330;
RX   PubMed=8385084;
RX   PubMed=8626706;
RX   PubMed=8806092;
RX   PubMed=10358721;
RX   PubMed=10700174;
RX   PubMed=11030152;
RX   PubMed=11551417;
RX   PubMed=11583962;
RX   PubMed=12068308;
RX   PubMed=12794755;
RX   PubMed=15746151;
RX   PubMed=15748285;
RX   PubMed=15900046;
RX   PubMed=17088437;
RX   PubMed=17332333;
RX   PubMed=18083107;
RX   PubMed=19372543;
RX   PubMed=19472407;
RX   PubMed=19941903;
RX   PubMed=20164919;
RX   PubMed=20215515;
RX   PubMed=20510196;
RX   PubMed=20557307;
RX   PubMed=22068913;
RX   PubMed=22336246;
RX   PubMed=22347499;
RX   PubMed=22384151;
RX   PubMed=22460905;
RX   PubMed=22628656;
RX   PubMed=22961666;
RX   PubMed=23381221;
RX   PubMed=23856246;
RX   PubMed=23933261;
RX   PubMed=24135919;
RX   PubMed=24279929;
RX   PubMed=24465237;
RX   PubMed=24670534;
RX   PubMed=25120651;
RX   PubMed=25485619;
RX   PubMed=25877200;
RX   PubMed=26589293;
RX   PubMed=27377824;
RX   PubMed=27397505;
RX   PubMed=27807467;
RX   PubMed=28196595;
RX   PubMed=28408844;
RX   PubMed=29444439;
RX   PubMed=29681454;
RX   PubMed=30038707;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=31803961;
RX   PubMed=31978347;
RX   PubMed=33425914;
RX   PubMed=35839778;
WW   https://dtp.cancer.gov/discovery_development/nci-60/cell_list.htm
WW   https://strap.nci.nih.gov/celline_detail.php?sample_id=12
WW   https://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/n/cell-lines-detail-613.html
WW   https://tcpaportal.org/mclp/
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: EGFR genetic alteration cell panel (ATCC TCP-1027).
CC   Part of: JFCR39 cancer cell line panel.
CC   Part of: KuDOS 95 cell line panel.
CC   Part of: MD Anderson Cell Lines Project.
CC   Part of: NCI-60 cancer cell line panel.
CC   Population: Caucasian.
CC   Characteristics: Expresses HPRT1 at the surface of the cell membrane (PubMed=28408844).
CC   Doubling time: 33 hours (Note=In RPMI 1640 + 10% FBS), 60 hours (Note=In ACL-3), 42 hours (Note=In ACL-3 + BSA) (PubMed=3940644); 19 hours (PubMed=7718330); 0.8 days (PubMed=11551417); 21.5 hours (PubMed=29681454); 18.39 +- 1.35 hours (PubMed=33425914); ~23 hours (DSMZ=ACC-737); 17.8 hours (NCI-DTP=NCI-H460).
CC   HLA typing: A*24,68; B*35,51; C*03,15; DQB1*03:01:01,05:01:01; DRB1*01,04 (PubMed=15748285).
CC   HLA typing: A*24:02,68:01; B*35:01,51:01; C*03:03,15:02 (PubMed=26589293).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; HGNC:6407; KRAS; Simple; p.Gln61His (c.183A>T); ClinVar=VCV000045117; Zygosity=Homozygous (PubMed=12068308; PubMed=12794755; PubMed=17088437; DepMap=ACH-000463).
CC   Sequence variation: Mutation; HGNC; HGNC:8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (PubMed=17088437).
CC   Sequence variation: Mutation; HGNC; HGNC:11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (PubMed=17088437).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; None_reported; -; Zygosity=- (PubMed=1311061; PubMed=15900046; PubMed=20557307).
CC   Omics: Array-based CGH.
CC   Omics: CNV analysis.
CC   Omics: Deep exome analysis.
CC   Omics: Deep phosphoproteome analysis.
CC   Omics: Deep proteome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: Fluorescence phenotype profiling.
CC   Omics: lncRNA expression profiling.
CC   Omics: Metabolome analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=0%; Native American=0%; East Asian, North=1.96%; East Asian, South=0%; South Asian=0.15%; European, North=65.65%; European, South=32.24% (PubMed=30894373).
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
ST   Source(s): AddexBio=C0016003/39; ATCC=HTB-177; CCRID; Cosmic-CLP=905943; DSMZ=ACC-737; KCLB=30177; PubMed=19372543; PubMed=25877200; PubMed=33425914; Technion Genomics Center
ST   Amelogenin: X,Y
ST   CSF1PO: 11,12
ST   D10S1248: 13
ST   D12S391: 21
ST   D13S317: 13
ST   D16S539: 9
ST   D18S51: 13,15
ST   D19S433: 14
ST   D1S1656: 11,14.3
ST   D21S11: 30
ST   D22S1045: 17
ST   D2S1338: 17,25
ST   D2S441: 11,11.3
ST   D3S1358: 15,18
ST   D5S818: 9,10
ST   D7S820: 9,12
ST   D8S1179: 12
ST   DYS391: 11
ST   FGA: 21,23
ST   Penta D: 11,13
ST   Penta E: 5
ST   TH01: 9.3
ST   TPOX: 8
ST   vWA: 17
DI   NCIt; C4450; Lung large cell carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   Age unspecified
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 19-12-24; Version: 50
//
genetic reprogramming by naive conditions establishes an
RT   irreversible state of partial X chromosome reactivation in female stem
RT   cells.";
RL   Oncotarget 9:25136-25147(2018).
//
 and p15 (MTS2) alterations
RT   preferentially in non-small cell lung cancers.";
RL   Cancer Res. 55:514-517(1995).
//
   recurrence in a human myoblast model of rhabdomyosarcoma.";
RL   J. Pathol. 241:626-637(2017).
//
 and specific for small cell carcinoma of the
RT   ovary, hypercalcaemic type.";
RL   J. Pathol. 238:389-400(2016).
//
osado M., Lutzky J., Bhalla K.N., Baker M.A., Taub R.N.;
RT   "Intracellular distribution and pharmacokinetics of daunorubicin in
RT   anthracycline-sensitive and -resistant HL-60 cells.";
RL   Cancer Res. 49:4607-4614(1989).
//
lved lymph
RT   node.";
RL   Cancer Res. 47:5181-5188(1987).
//
mmunol. 19:1477-1483(1989).
//
s.";
RL   Leuk. Res. 9:97-111(1985).
//
  structure.";
RL   J. Bone Miner. Res. 34:979-995(2019).
//
C87421;
RA   Rodriguez-Roche R., Alvarez M., Guzman Tirado M.G., Morier L.,
RA   Kouri Flores G.P.;
RT   "Comparison of rapid centrifugation assay with conventional tissue
RT   culture method for isolation of dengue 2 virus in C6/36-HT cells.";
RL   J. Clin. Microbiol. 38:3508-3510(2000).
//
 Yoshino T., Takada K., Oka T., Hayashi K.,
RA   Akagi T.;
RT   "Characterization of Epstein-Barr virus-infected mantle cell lymphoma
RT   lines.";
RL   Acta Med. Okayama 54:193-200(2000).
//
=3065655;
RA   Svec J., Veselovska Z., Keszeghova V., Matoska J., Marchetti A.,
RA   Squartini F.;
RT   "Biological and immunological properties of the HMB-2 human melanoma
RT   cell line.";
RL   Neoplasma 35:665-681(1988).
//
ayashi Y., Schlieve C.R., Ikeya M., Kim H.,
RA   Nguyen T.D., Sami S., Baba S., Barruet E., Nasu A., Asaka I.,
RA   Otsuka T., Yamanaka S., Conklin B.R., Toguchida J., Hsiao E.C.;
RT   "Induced pluripotent stem cells from patients with human
RT   fibrodysplasia ossificans progressiva show increased mineralization
RT   and cartilage formation.";
RL   Orphanet J. Rare Dis. 8:190.1-190.14(2013).
//
   Reinhold W.C., Weinstein J.N., Stratton M.R., Futreal P.A., Wooster R.;
RT   "Mutation analysis of 24 known cancer genes in the NCI-60 cell line
RT   set.";
RL   Mol. Cancer Ther. 5:2606-2612(2006).
//
he
RT   invasive front of early-stage lung adenocarcinomas.";
RL   Am. J. Pathol. 160:1129-1141(2002).
//
eneration.";
RL   NPJ Regen. Med. 4:19-19(2019).
//
carcinoma --
RT   SINJ -- phenotypic analysis and in vivo carcinogenesis.";
RL   Int. J. Oncol. 2:831-836(1993).
//
146; DOI=10.1089/hyb.2009.0059;
RA   Wang Y.-C., Zheng L.-H., Ma B.-A., Zhou Y., Fan Q.-Y.;
RT   "Generation and identification of monoclonal antibodies against FNIII
RT   domain D of human tenascin-C.";
RL   Hybridoma 29:13-16(2010).
//
r G.;
RT   "Attachment protein G of an African bat henipavirus is differentially
RT   restricted in chiropteran and nonchiropteran cells.";
RL   J. Virol. 88:11973-11980(2014).
//
 M., Lindstrom A.-C., Gaugaz F.Z.,
RA   Matsson P., Artursson P.;
RT   "Complete knockout of endogenous Mdr1 (Abcb1) in MDCK cells by
RT   CRISPR-Cas9.";
RL   J. Pharm. Sci. 105:1017-1021(2016).
//
of pituitary cells
RT   captures three novel cell lines in the Pit-1 lineage.";
RL   Mol. Endocrinol. 24:2232-2240(2010).
//
T   established osteosarcoma lung metastases.";
RL   Cancer Res. 72:271-281(2012).
//
, Miranda C.L., Buhler D.R., Barnes D.W.;
RT   "Culture of cells from zebrafish (Brachydanio rerio) embryo and adult
RT   tissues.";
RL   Cell Biol. Toxicol. 8:43-61(1992).
//
., von Kleist-Retzow J.-C.,
RA   Smeitink J.A.M., Nijtmans L.G.J., van den Heuvel L.P.W.J.;
RT   "Novel mutations in the NDUFS1 gene cause low residual activities in
RT   human complex I deficiencies.";
RL   Mol. Genet. Metab. 100:251-256(2010).
//
mouse fibroblasts carrying human beta-2
RT   microglobulin.";
RL   Immunogenetics 22:1-8(1985).
//
   Takano A., Araki K., Akimaru K., Yuri K.;
RT   "Conventional and molecular cytogenetic characterization of a new
RT   human cell line, GIST-T1, established from gastrointestinal stromal
RT   tumor.";
RL   Lab. Invest. 82:663-665(2002).
//
and transcriptional upregulation of the
RT   sarco/endoplasmic reticulum Ca2+ transport ATPase in
RT   thapsigargin-resistant hamster smooth muscle cells.";
RL   Nucleic Acids Res. 26:4529-4537(1998).
//
C., Chen J.-Y.,
RA   Morelli E., Waszyk P., Kumar S., Deming D., Moret N., Rodriguez S.,
RA   Subramanian K., Rogava M., Cartwright A.N.R., Luoma A., Mei S.-L.,
RA   Brinker T.J., Miller D.M., Spektor A., Schadendorf D., Riggi N.,
RA   Wucherpfennig K.W., Sorger P.K., Izar B.;
RT   "Inhibition of haspin kinase promotes cell-intrinsic and extrinsic
RT   antitumor activity.";
RL   Cancer Res. 80:798-810(2020).
//
.
//
 for an increase in the resistant
RT   population following transformation.";
RL   Carcinogenesis 4:857-861(1983).
//
; PMCID=PMC4960662;
RA   Kleensang A., Vantangoli M.M., Odwin-DaCosta S., Andersen M.E.,
RA   Boekelheide K., Bouhifd M., Fornace A.J. Jr., Li H.-H., Livi C.B.,
RA   Madnick S., Maertens A., Rosenberg M., Yager J.D., Zhaog L.,
RA   Hartung T.;
RT   "Genetic variability in a frozen batch of MCF-7 cells invisible in
RT   routine authentication affecting cell function.";
RL   Sci. Rep. 6:28994-28994(2016).
//
.25.559255;
RA   Adriaenssens E., Nguyen T.N., Sawa-Makarska J., Khuu G.,
RA   Schuschnig M., Watts E.M., Shoebridge S., Csalyi K.D., Padman B.S.,
RA   Lazarou M., Martens S.;
RT   "Control of mitophagy initiation and progression by the TBK1 adaptors
RT   NAP1 and SINTBAD.";
RL   bioRxiv 2023:09.25.559255-09.25.559255(2023).
//
9664;
RA   Francke U., Taggart R.T.;
RT   "Comparative gene mapping: order of loci on the X chromosome is
RT   different in mice and humans.";
RL   Proc. Natl. Acad. Sci. U.S.A. 77:3595-3599(1980).
//
ion.";
RL   Proc. Natl. Acad. Sci. U.S.A. 77:4113-4117(1980).
//
47:4068-4085(2019).
//

RT   modeling.";
RL   Stem Cell Res. 23:73-76(2017).
//
6-4;
RA   Kaiser-McCaw Hecht B., Epstein A.L., Berger C.S., Kaplan H.S.,
RA   Hecht F.;
RT   "Histiocytic lymphoma cell lines: immunologic and cytogenetic
RT   studies.";
RL   Cancer Genet. Cytogenet. 14:205-218(1985).
//
ins D.W., Brinckerhoff C.E.;
RT   "Multiple murine BRaf(V600E) melanoma cell lines with sensitivity to
RT   PLX4032.";
RL   Pigment Cell Melanoma Res. 27:495-501(2014).
//
vanced stages of oral
RT   squamous cell carcinoma.";
RL   Cancer Sci. 97:1351-1358(2006).
//
  Cell Stem Cell 8:357-359(2011).
//
87; DOI=10.1038/nature09671; PMCID=PMC5024568;
RA   Ngo V.N., Young R.M., Schmitz R., Jhavar S., Xiao W.-M., Lim K.-H.,
RA   Kohlhammer H., Xu W.-H., Yang Y.-D., Zhao H., Shaffer A.L. 3rd,
RA   Romesser P.B., Wright G., Powell J.I., Rosenwald A.,
RA   Muller-Hermelink H.-K., Ott G., Gascoyne R.D., Connors J.M.,
RA   Rimsza L.M., Campo E., Jaffe E.S., Delabie J., Smeland E.B.,
RA   Fisher R.I., Braziel R.M., Tubbs R.R., Cook J.R., Weisenburger D.D.,
RA   Chan W.-C., Staudt L.M.;
RT   "Oncogenically active MYD88 mutations in human lymphoma.";
RL   Nature 470:115-119(2011).
//
ystemic chemotherapy of murine bladder cancer.";
RL   Cancer Res. 37:2918-2929(1977).
//
p.1840180216;
RA   Yano H., Iemura A., Fukuda K., Mizoguchi A., Haramaki M., Kojiro M.;
RT   "Establishment of two distinct human hepatocellular carcinoma cell
RT   lines from a single nodule showing clonal dedifferentiation of cancer
RT   cells.";
RL   Hepatology 18:320-327(1993).
//
tor detected
RT   by a monoclonal antibody.";
RL   Proc. Natl. Acad. Sci. U.S.A. 83:7888-7892(1986).
//
, Mirakhori M., Roozafzoon R., Rajabi M.T.,
RA   Tabatabaie S.Z., Farzanfar F., Khoshzaban A., Asadi-Amoli F.;
RT   "Isolation and characterization of a new cell line of
RT   retinoblastoma.";
RL   PeerJ PrePrints 5:e2780v1-e2780v1(2017).
//
0.1038/nature05329; PMCID=PMC2669898;
RA   Redon R., Ishikawa S., Fitch K.R., Feuk L., Perry G.H., Andrews T.D.,
RA   Fiegler H., Shapero M.H., Carson A.R., Chen W.-W., Cho E.K., Dallaire S.,
RA   Freeman J.L., Gonzalez J.R., Gratacos M., Huang J., Kalaitzopoulos D.,
RA   Komura D., MacDonald J.R., Marshall C.R., Mei R., Montgomery L.,
RA   Nishimura K., Okamura K., Shen F., Somerville M.J., Tchinda J.,
RA   Valsesia A., Woodwark C., Yang F.-T., Zhang J.-J., Zerjal T., Zhang J.,
RA   Armengol L., Conrad D.F., Estivill X., Tyler-Smith C., Carter N.P.,
RA   Aburatani H., Lee C., Jones K.W., Scherer S.W., Hurles M.E.;
RT   "Global variation in copy number in the human genome.";
RL   Nature 444:444-454(2006).
//
azquez E.J., Weber K.S.,
RA   Robison R.A., O'Neill K.L.;
RT   "Non-small-cell lung cancer cell lines A549 and NCI-H460 express
RT   hypoxanthine guanine phosphoribosyltransferase on the plasma
RT   membrane.";
RL   Onco Targets Ther. 10:1921-1932(2017).
//
occuni P., Di Noto R., Del Vecchio L., Salvatore F., Rotoli B.;
RT   "Coexistence of two distinct cell populations (CD56(+)TcRgammadelta(+)
RT   and CD56(+)TcRgammadelta(-)) in a case of aggressive CD56(+)
RT   lymphoma/leukemia.";
RL   Haematologica 85:496-501(2000).
//

RT   ovary cell.";
RL   Somatic Cell Genet. 9:165-173(1983).
//
E., Maiorana L., Vasta V., Pezzino F.M., Sunkara S., Wynne K.,
RA   Elia G., Marincola F.M., McCubrey J.A., Libra M., Travali S., Kane M.;
RT   "Characterization of human melanoma cell lines and melanocytes by
RT   proteome analysis.";
RL   Cell Cycle 10:2924-2936(2011).
//
  "Normal human fibroblasts are resistant to RAS-induced senescence.";
RL   Mol. Cell. Biol. 24:2842-2852(2004).
//
col. 28:461-464(1991).
//
RT   bead-based isolation and characterization of its CD90/CD44
RT   subpopulations.";
RL   Oncotarget 8:66254-66269(2017).
//
sner A., Musunuru K., Kathiresan S.,
RA   Daheron L., Zhu J., Gerszten R.E., Deo R.C., Vasan R.S.,
RA   O'Donnell C.J., Cowan C.A.;
RT   "Induced pluripotent stem cell differentiation enables functional
RT   validation of GWAS variants in metabolic disease.";
RL   Cell Stem Cell 20:547-557.e7(2017).
//
0/15384101.2017.1371880; PMCID=PMC5638364;
RA   Moraleva A., Magoulas C., Polzikov M.A., Hacot S., Mertani H.C.,
RA   Diaz J.-J., Zatsepina O.V.;
RT   "Involvement of the specific nucleolar protein SURF6 in regulation of
RT   proliferation and ribosome biogenesis in mouse NIH/3T3 fibroblasts.";
RL   Cell Cycle 16:1979-1991(2017).
//
371/journal.pone.0008067; PMCID=PMC2780725;
RA   Takahashi K., Narita M., Yokura M., Ichisaka T., Yamanaka S.;
RT   "Human induced pluripotent stem cells on autologous feeders.";
RL   PLoS ONE 4:E8067-E8067(2009).
//
hatic vessel endothelial hyaluronan receptor 1.";
RL   Cancer Sci. 109:3171-3182(2018).
//
ussell E., Johnson B., Buchhagen D.L., Bodner S.M., Phelps R.M.,
RA   Gazdar A.F., Minna J.D.;
RT   "High frequency of somatically acquired p53 mutations in small-cell
RT   lung cancer cell lines and tumors.";
RL   Oncogene 7:339-346(1992).
//
Med=9817906; DOI=10.1128/jcm.36.12.3718-3720.1998; PMCID=PMC105273;
RA   Schultz-Cherry S., Dybdahl-Sissoko N., McGregor M., Hinshaw V.S.;
RT   "Mink lung epithelial cells: unique cell line that supports influenza
RT   A and B virus replication.";
RL   J. Clin. Microbiol. 36:3718-3720(1998).
//
.,
RA   Osborne B.;
RT   "Characterization of a mutant T-cell hybridoma line with defects in
RT   the TCR-mediated apoptotic pathway.";
RL   Cell Death Differ. 6:36-47(1999).
//
., Brown A.M., Wellner R.B., Baum B.J.;
RT   "Characteristics of alpha 1-adrenergic receptors in a rat salivary
RT   cell line, RSMT-A5.";
RL   Gen. Pharmacol. 20:175-181(1989).
//
omi M., Goto S.;
RT   "Correction to: Aurora B kinase as a therapeutic target in acute
RT   lymphoblastic leukemia.";
RL   Cancer Chemother. Pharmacol. 88:1055-1056(2021).
//